Polyostotic Fibrous Dysplasia Clinical Trial
Official title:
A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome
This study will examine the effect of pegvisomant on growth hormone excess in patients with
McCune-Albright syndrome (MAS). Patients with this disease have polyostotic fibrous
dysplasia-a condition in which areas of normal bone are replaced with fibrous growth similar
to scar tissue, abnormal skin pigmentation (birth marks) and precocious (early) puberty.
About 10 percent of patients have excess growth hormone (GH). GH stimulates the production
of another hormone called insulin-like growth factor 1 (IGF-1). Together, GH and IGF-1
affect bone growth. The excess of these hormones in MAS can cause overgrowth of the bones of
the face, hands and feet, excess sweating, or increased height.
Pegvisomant is a synthetic drug that binds to cell receptors where GH would normally bind,
thus preventing the naturally occurring hormone from stimulating IGF-1 and bone growth as it
normally would. This study will see if pegvisomant will reduce blood levels of IGF-1 and
mitigate the effects of growth hormone excess, including bone pain, bone turnover, hand and
foot swelling and sweating, and abnormal levels of related hormones.
Patients who were screened for polyostotic fibrous dysplasia and MAS under NIH protocol
98-D-0145 and were found to have MAS with excess growth hormone are eligible for this
36-week study. The screening protocol includes a history and physical examination, blood and
urine tests, hearing, eye and dental examinations, pain and physical function evaluations,
endocrine and bone screening tests, various bone imaging studies, including magnetic
resonance imaging (MRI) and computed tomography (CT) scans and bone biopsy in patients over
6 years old.
Participants in the current study will receive daily injections of either pegvisomant or
placebo (an inactive substance) for 12 weeks, followed by a 6-week "washout" period with no
drug. Then, patients who received placebo will be switched, or "crossed over," to receive
pegvisomant for another 12 weeks, and those who received pegvisomant will receive placebo.
This will be followed by another 6-week washout period. The drug and placebo will be
injected under the skin, similar to insulin injections. Blood and urine tests will be done
at the beginning of the study and repeated every 6 weeks until the study ends.
McCune-Albright Syndrome (MAS) was originally described as the triad of polyostotic fibrous
dysplasia of bone, cafe-au-lait skin pigmentation and precocious puberty. Other endocrine
abnormalities have been identified in this disease. Growth hormone (GH) excess is associated
with MAS and occurs in approximately 10% of the patients. Current therapies of MAS involve
separate treatment for the bone and endocrine diseases. We propose to test the effectiveness
of a novel GH receptor antagonist, pegvisomant at reducing the growth hormone excess in
these patients. Secondarily we shall also assess the impact of pegvisomant therapy on the
fibrous dysplastic bone lesions associated with the disease.
The subjects will be patients with MAS and non-suppressible growth hormone as determined by
standard oral glucose tolerant testing (OGTT) and an elevated insulin-like growth factor-1
(IGF-I). It will be a randomized, blinded crossover design. The primary and secondary
measures of efficacy will be: the normalization of serum (IGF-I), a reduction in signs and
symptoms of growth hormone excess, and a net change in Insulin-like Growth Factor Binding
Protein 3 (IGFBP-3). The effect of pegvisomant on the fibrous dysplastic bone activity in
these patients will be determined by a net change in the levels of bone turnover markers.
;
Endpoint Classification: Efficacy Study, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00001181 -
Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty
|
Phase 2 | |
| Completed |
NCT00001973 -
Studies on Abnormal Bone From Patients With Polyostotic Fibrous Dysplasia and McCune Albright Syndrome
|
N/A | |
| Completed |
NCT00001851 -
Bone Marrow Injection to Replace Diseased Bone in Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome
|
N/A | |
| Completed |
NCT00006174 -
Effects of Letrozole on Precocious Puberty Due to McCune Albright Syndrome
|
Phase 1 | |
| Completed |
NCT00001728 -
Alendronate to Treat Polyostotic Fibrous Dysplasia and McCune-Albright Syndrome
|
Phase 2 |